- €111.93m
- €82.73m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.02 | ||
| Price to Tang. Book | 1.02 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.89% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 34.9 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -97.17 | +704.66 | -93.81 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Malin Corporation PLC is focused on investing in life sciences companies. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, CG Oncology, Wren, KNOW Bio and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of hematological malignancies, including multiple myeloma, and solid tumours, like prostate cancer. It is also developing two CAR-T therapies: autologous and allogeneic. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder-saving therapeutics for patients with bladder cancer.
Directors
- Liam Daniel NEC (63)
- Bahija Jallal CEO (59)
- Darragh Lyons CFO (35)
- Neil McLoughlin GCN
- David Dobrosky OTH
- Fiona Dunlevy OTH
- Peter Schwartzman OTH
- Luke Corning NED (39)
- Jean-Michel Cossery NED
- Kirsten Drejer NED (65)
- Owen Hughes NED (46)
- Robert Ingram NED
- Rudy Mareel NED
- G. Kelly Martin NED (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 16th, 2014
- Public Since
- March 25th, 2015
- No. of Employees
- 3
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Irish Stock Exchange- Shares in Issue
- 18,971,256
- Address
- The Lennox Building, DUBLIN, D02 FK02
- Web
- http://malinplc.com/
- Phone
- +353 19015700
- Auditors
- KMPG
Latest News for MLC
Upcoming Events for MLC
Half Year 2024 Malin Corporation PLC Earnings Release
Similar to MLC
Uniphar
Irish Stock Exchange
FAQ
As of Today at 19:13 UTC, shares in Malin are trading at €5.90. This share price information is delayed by 15 minutes.
Shares in Malin last closed at €5.90 and the price had moved by +5.36% over the past 365 days. In terms of relative price strength the Malin share price has outperformed the FTSE Global All Cap Index by +3.54% over the past year.
The overall consensus recommendation for Malin is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Malin does not currently pay a dividend.
Malin does not currently pay a dividend.
Malin does not currently pay a dividend.
To buy shares in Malin you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €5.90, shares in Malin had a market capitalisation of €111.93m.
Here are the trading details for Malin:
- Country of listing: Ireland
- Exchange: ISE
- Ticker Symbol: MLC
Based on an overall assessment of its quality, value and momentum Malin is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Malin is €11.70. That is 98.31% above the last closing price of €5.90.
Analysts covering Malin currently have a consensus Earnings Per Share (EPS) forecast of -€0.11 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Malin. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +24.92%.
As of the last closing price of €5.90, shares in Malin were trading +22.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Malin PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €5.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Malin's management team is headed by:
- Liam Daniel - NEC
- Bahija Jallal - CEO
- Darragh Lyons - CFO
- Neil McLoughlin - GCN
- David Dobrosky - OTH
- Fiona Dunlevy - OTH
- Peter Schwartzman - OTH
- Luke Corning - NED
- Jean-Michel Cossery - NED
- Kirsten Drejer - NED
- Owen Hughes - NED
- Robert Ingram - NED
- Rudy Mareel - NED
- G. Kelly Martin - NED